Cellosaurus logo
expasy logo

Cellosaurus MIA PaCa-2 (CVCL_0428)

[Text version]
Cell line name MIA PaCa-2
Synonyms MIA-PaCa-2; MIA-PACA-2; MIA-Pa-Ca-2; MIA Paca2; MIA PaCa2; MiaPaCa-2; MIAPACA-2; MiaPaca.2; MiaPaCa2; Miapaca2; MIAPaCa2; MIAPACA2; Mia PACA 2; MIAPaCa-2; PaCa2; MiaPaCa
Accession CVCL_0428
Resource Identification Initiative To cite this cell line use: MIA PaCa-2 (RRID:CVCL_0428)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI RAS program mutant KRAS cell line panel.
Population: Caucasian.
Doubling time: 26 hours (PubMed=25984343); 25.7 +- 4.3 hours (PubMed=27067801); 40 hours, 18 hours (Note=In serum-free medium) (PubMed=23386380); ~40 hours (ATCC=CRL-1420); ~30-40 hours (DSMZ=ACC-733).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Metabolome analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Secretome proteome analysis by 2D-DE/MS.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Caution: Additional TP53 mutation in c.818G>A indicated incorrectly in PubMed=1630814.
Misspelling: MiaPaCa-1; PubMed=15770730.
Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
Sequence variations
HLA typing Source: PubMed=18575732
Class I
HLA-AA*02,24
HLA-BB*01,46
HLA-CC*03

Source: CLS=300438
Class I
HLA-AA*24:02:01
HLA-BB*14:02:01
HLA-CC*08:02:01
Class II
HLA-DPDPB1*02:01:02
HLA-DQDQA1*01:01:02
DQB1*05:01:01
HLA-DRDRB1*01:02:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.15
Native American0
East Asian, North3.82
East Asian, South0
South Asian8.7
European, North22.54
European, South63.79
Disease Pancreatic ductal adenocarcinoma (NCIt: C9120)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_HA89 (GEM-MIA PaCa-2)CVCL_WI23 (MIA PaCa-2 GR2000)CVCL_WI24 (MIA PaCa-2 GR300)
CVCL_WI25 (MIA PaCa-2 GR800)CVCL_JG54 (MIA PaCa-2/CMV-Luc)CVCL_C7SQ (MiaPaCa(BCRP))
CVCL_D282 (PH61-N)
Sex of cell Male
Age at sampling 65Y
Category Cancer cell line
STR profile Source(s): AddexBio=C0018002/59; ATCC=CRL-1420; CCRID; Cosmic-CLP=724870; DSMZ=ACC-733; ECACC=85062806; JCRB=JCRB0070; KCLB=21420; PubMed=17254797; PubMed=25877200; RCB=RCB2094; Technion Genomics Center; TKG=TKG 0227

Markers:
AmelogeninX
CSF1PO10
D1S165615,17.3
D2S44114
D2S133825
D3S135816
D5S81812,13 (AddexBio=C0018002/59; ATCC=CRL-1420; CCRID; Cosmic-CLP=724870; DSMZ=ACC-733; ECACC=85062806; JCRB=JCRB0070; PubMed=25877200; RCB=RCB2094; Technion Genomics Center; TKG=TKG 0227)
13 (PubMed=17254797)
D6S104312
D7S82012 (KCLB=21420)
12,13 (AddexBio=C0018002/59; ATCC=CRL-1420; CCRID; Cosmic-CLP=724870; DSMZ=ACC-733; ECACC=85062806; JCRB=JCRB0070; PubMed=17254797; PubMed=25877200; RCB=RCB2094; Technion Genomics Center; TKG=TKG 0227)
D8S117916
D10S124814,15
D12S39119
D13S31712,13
D16S53910,13 (AddexBio=C0018002/59; ATCC=CRL-1420; CCRID; Cosmic-CLP=724870; DSMZ=ACC-733; ECACC=85062806; JCRB=JCRB0070; PubMed=25877200; RCB=RCB2094; Technion Genomics Center; TKG=TKG 0227)
11,13 (PubMed=17254797)
D18S5112
D19S43315
D21S1129,31 (PubMed=17254797)
29,31.2 (ATCC=CRL-1420; CCRID; DSMZ=ACC-733; PubMed=25877200; Technion Genomics Center)
D22S104516
FGA22
Penta D12,16
Penta E13,18
TH019,10
TPOX9
vWA15

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/MIA_PaCa-2
https://www.cellosaurus.org/pawefish/PancCellLineDescriptions/MIA%20PaCA-2.html
http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MIA%20PaCa-2
https://strap.nci.nih.gov/celline_detail.php?sample_id=64
https://tcpaportal.org/mclp/
Publications

PubMed=1764370; DOI=10.1038/bjc.1991.467; PMCID=PMC1977874
Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N., Lane D.P., Lemoine N.R.
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
Br. J. Cancer 64:1076-1082(1991)

PubMed=1630814
Ruggeri B., Zhang S.-Y., Caamano J., DiRado M., Flynn S.D., Klein-Szanto A.J.P.
Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.
Oncogene 7:1503-1511(1992)

PubMed=7809022; DOI=10.1097/00006676-199409000-00018
Sumi S., Beauchamp R.D., Townsend C.M. Jr., Pour P.M., Ishizuka J., Thompson J.C.
Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation.
Pancreas 9:657-661(1994)

PubMed=7961102; DOI=10.1111/j.1349-7006.1994.tb02898.x; PMCID=PMC5919355
Suwa H., Yoshimura T., Yamaguchi N., Kanehira K., Manabe T., Imamura M., Hiai H., Fukumoto M.
K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.
Jpn. J. Cancer Res. 85:1005-1014(1994)

PubMed=8026879; DOI=10.1002/ijc.2910580207
Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.
Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.
Int. J. Cancer 58:185-191(1994)

PubMed=8194712; DOI=10.1016/0016-5085(94)90422-7
Simon B., Weinel R., Hohne M., Watz J., Schmidt J., Kortner G., Arnold R.
Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma.
Gastroenterology 106:1645-1651(1994)

PubMed=21607521; DOI=10.3892/or.1.6.1223
Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y., Shimazoe T., Nawata H., Kono A.
Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in human pancreatic cancer-derived cell-lines with different metastatic potential.
Oncol. Rep. 1:1223-1227(1994)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4; PMCID=PMC1850008
Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
Am. J. Pathol. 154:525-536(1999)

PubMed=11115575; DOI=10.3892/or.8.1.89
Sun C.-L., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.
Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.
Oncol. Rep. 8:89-92(2001)

PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U
Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.
Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.
Int. J. Cancer 91:340-344(2001)

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C
Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.
Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.
Int. J. Cancer 91:350-358(2001)

PubMed=11787853; DOI=10.1007/s004280100474
Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr J.-M., Scarpa A.
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
Virchows Arch. 439:798-802(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=12692724; DOI=10.1007/s00428-003-0784-4
Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.
Virchows Arch. 442:444-452(2003)

PubMed=14695172
Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L.-C., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M.G., Hruban R.H.
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
Cancer Res. 63:8614-8622(2003)

PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521; PMCID=PMC4305696
Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W., Marten A.
Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
World J. Gastroenterol. 11:1521-1528(2005)

PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721
Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E., Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H., Kern S.E.
Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.
Cancer Res. 66:7920-7928(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)

PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x; PMCID=PMC3828895
Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr J.-M., Jesenofsky R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling.
J. Cell. Mol. Med. 12:2823-2835(2008)

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x; PMCID=PMC11158928
Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Cancer Sci. 99:986-994(2008)

PubMed=18575732; DOI=10.3892/or.20.1.155
Kawaoka T., Oka M., Takashima M., Ueno T., Yamamoto K., Yahara N., Yoshino S., Hazama S.
Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Oncol. Rep. 20:155-163(2008)

CLPUB00416
Oberlin L.
Treatment of pancreatic carcinoma cell lines in vitro and vivo with a monoclonal antibody against the transferrin receptor.
Thesis VMD (2009); Justus-Liebig-Universitat Giessen; Giessen; Germany

PubMed=19077451; DOI=10.1159/000178871
Harada T., Chelala C., Crnogorac-Jurcevic T., Lemoine N.R.
Genome-wide analysis of pancreatic cancer using microarray-based techniques.
Pancreatology 9:13-24(2009)

PubMed=19188929; DOI=10.1038/tpj.2008.20
Guo J., Anderson M.G., Tapang P., Palma J.P., Rodriguez L.E., Niquette A.L., Li J.-L., Bouska J.J., Wang G., Semizarov D., Albert D.H., Donawho C.K., Glaser K.B., Shah O.J.
Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
Pharmacogenomics J. 9:90-102(2009)

PubMed=20037478; DOI=10.4161/cbt.8.21.9685; PMCID=PMC2824894
Kent O.A., Mullendore M.E., Wentzel E.A., Lopez-Romero P., Tan A.-C., Alvarez H., West K.M., Ochs M.F., Hidalgo M., Arking D.E., Maitra A., Mendell J.T.
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.
Cancer Biol. Ther. 8:2013-2024(2009)

PubMed=19904223; DOI=10.1097/MPA.0b013e3181bc44dd; PMCID=PMC2835986
Xiao J., Lee W.-N.P., Zhao Y.-C., Cao R., Go V.L.-W., Recker R.R., Wang Q., Xiao G.G.-S.
Profiling pancreatic cancer-secreted proteome using 15N amino acids and serum-free media.
Pancreas 39:e17-e23(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963; PMCID=PMC2860631
Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J.
Phenotype and genotype of pancreatic cancer cell lines.
Pancreas 39:425-435(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

DOI=10.4172/2324-9293.1000104
Wagenhauser M.U., Ruckert F., Niedergethmann M., Grutzmann R., Saeger H.-D.
Distribution of characteristic mutations in native ductal adenocarcinoma of the pancreas and pancreatic cancer cell lines.
Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013)

PubMed=23386380; DOI=10.1002/jcb.24506
Bose B., Shenoy P.S.
Non insulin producing cell line, MIA PaCa-2 is rendered insulin producing in vitro via mesenchymal epithelial transition.
J. Cell. Biochem. 114:1642-1652(2013)

PubMed=25167228; DOI=10.1038/bjc.2014.475; PMCID=PMC4453732
Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Br. J. Cancer 111:1788-1801(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25485960; DOI=10.4161/15384047.2014.986967; PMCID=PMC4623403
Samulitis B.K., Pond K.W., Pond E., Cress A.E., Patel H., Wisner L., Patel C., Dorr R.T., Landowski T.H.
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
Cancer Biol. Ther. 16:43-51(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26216984; DOI=10.1073/pnas.1501605112; PMCID=PMC4538616
Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)

PubMed=27067801; DOI=10.1186/s12885-016-2297-y; PMCID=PMC4828819
Miura K., Kimura K., Amano R., Yamazoe S., Ohira G., Murata A., Nishio K., Hasegawa T., Yashiro M., Nakata B., Ohira M., Hirakawa K.
Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2.
BMC Cancer 16:268.1-268.13(2016)

PubMed=27259358; DOI=10.1074/mcp.M116.058313; PMCID=PMC4974343
Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J.-M., Daly R.J.
Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.
Mol. Cell. Proteomics 15:2671-2685(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051; PMCID=PMC6343826
Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.
Differential effector engagement by oncogenic KRAS.
Cell Rep. 22:1889-1902(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31037374; DOI=10.1007/s00216-019-01814-1
Lagies S., Schlimpert M., Braun L.M., Kather M., Plagge J., Erbes T., Wittel U.A., Kammerer B.
Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry.
Anal. Bioanal. Chem. 411:6319-6328(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32782605; DOI=10.3892/ol.2020.11825; PMCID=PMC7400074
Takagi K., Imura J., Shimomura A., Noguchi A., Minamisaka T., Tanaka S., Nishida T., Hatta H., Nakajima T.
Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32.
Oncol. Lett. 20:2888-2896(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) AddexBio; C0018002/59
ATCC; CRL-1420
ATCC; CRM-CRL-1420
BCRC; 60139
BCRJ; 0174
CCTCC; GDC0255
CLS; 300438
DSMZ; ACC-733
ECACC; 85062806
IZSLER; BS TCL 42
JCRB; JCRB0070
KCLB; 21420
NCBI_Iran; C459
RCB; RCB2094
TKG; TKG 0227
Cell line databases/resources CLO; CLO_0007726
CLO; CLO_0050101
MCCL; MCC:0000325
CLDB; cl3480
CLDB; cl3481
CLDB; cl3482
cancercelllines; CVCL_0428
CCRID; 3101HUMSCSP568
CCRID; 4201HUM-CCTCC00255
Cell_Model_Passport; SIDM00505
CGH-DB; 321-1
CGH-DB; 9374-4
Cosmic-CLP; 724870
DepMap; ACH-000601
DSMZCellDive; ACC-733
FCS-free; 216-2-440-1-3-6
IGRhCellID; MIAPaCa
LINCS_LDP; LCL-1738
Lonza; 751
SKY/M-FISH/CGH; 1996
Anatomy/cell type resources BTO; BTO:0002137
Biological sample resources BioSample; SAMN01821579
BioSample; SAMN01821700
BioSample; SAMN03472131
BioSample; SAMN10988205
CRISP screens repositories BioGRID_ORCS_Cell_line; 544
Chemistry resources ChEMBL-Cells; CHEMBL3308500
ChEMBL-Targets; CHEMBL614725
GDSC; 724870
PharmacoDB; MIAPaCa2_931_2019
PubChem_Cell_line; CVCL_0428
Encyclopedic resources Wikidata; Q54905679
Experimental variables resources EFO; EFO_0002236
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM206526
GEO; GSM244425
GEO; GSM621895
GEO; GSM784703
GEO; GSM887320
GEO; GSM888396
GEO; GSM1024404
GEO; GSM1374677
GEO; GSM1374678
GEO; GSM1374679
GEO; GSM1435696
GEO; GSM1435697
GEO; GSM1435698
GEO; GSM1588612
GEO; GSM1588624
GEO; GSM1670109
Metabolomic databases MetaboLights; MTBLS812
Polymorphism and mutation databases Cosmic; 707249
Cosmic; 710861
Cosmic; 719677
Cosmic; 724644
Cosmic; 724870
Cosmic; 730532
Cosmic; 808172
Cosmic; 868243
Cosmic; 872996
Cosmic; 913313
Cosmic; 918056
Cosmic; 922249
Cosmic; 923170
Cosmic; 932520
Cosmic; 947399
Cosmic; 948373
Cosmic; 948731
Cosmic; 949234
Cosmic; 968107
Cosmic; 1006368
Cosmic; 1066202
Cosmic; 1108337
Cosmic; 1198208
Cosmic; 1299302
Cosmic; 1320461
Cosmic; 1366278
Cosmic; 1477431
Cosmic; 1571779
Cosmic; 1534318
Cosmic; 1609545
Cosmic; 1644314
Cosmic; 1995507
Cosmic; 2434084
Cosmic; 2664042
Cosmic; 2668287
Cosmic; 2755950
IARC_TP53; 316
LiGeA; CCLE_231
Progenetix; CVCL_0428
Proteomic databases PRIDE; PXD001260
PRIDE; PXD003198
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update10-Sep-2024
Version number47